Compare AMTB & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | EVO |
|---|---|---|
| Founded | 1979 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.1M | 934.1M |
| IPO Year | 2018 | N/A |
| Metric | AMTB | EVO |
|---|---|---|
| Price | $22.44 | $3.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $23.67 | $7.00 |
| AVG Volume (30 Days) | ★ 201.2K | 85.0K |
| Earning Date | 04-23-2026 | 04-08-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 386.36 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.29 | $1.37 |
| Revenue Next Year | $7.67 | $10.05 |
| P/E Ratio | $50.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.62 | $2.31 |
| 52 Week High | $24.38 | $4.48 |
| Indicator | AMTB | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 53.04 |
| Support Level | $21.98 | $2.88 |
| Resistance Level | $22.75 | $3.36 |
| Average True Range (ATR) | 0.57 | 0.09 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 49.13 | 54.34 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.